About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited functions as India’s leading pharmaceutical enterprise with the largest market position while maintaining its status as a major global pharmaceutical company. The Company distributes specialty medicines alongside branded generics alongside generics and active pharmaceutical ingredients (APIs) in both chronic and acute therapy segments across 100+ countries. The Company operates 40 manufacturing sites globally which span six continents while employing more than 43,000 people from 50 different nations through its extensive R&D facilities and clinical development network. The company manufactures tablets and capsules as well as injectables and sprays and ointments and creams and liquids which demonstrate its diverse product range and manufacturing presence. The financial records of the consolidated entity list 102 subsidiaries according to the entity schedule found in the Annual Report. The Company stands as the largest Indian pharmaceutical company in Emerging Markets alongside ranking as the 12th biggest generic pharmaceutical company in the United States. Sun Pharma expands its operations through innovative specialty drug launches while offering cost-effective generic medications and consumer healthcare solutions that match its mission to “Reaching People and Touching Lives Globally”  .

The India business segment of Sun Pharma operates alongside its international divisions that serve the US, Emerging Markets and Rest of the World (RoW). The company delivers its products in RoW markets including Western Europe and Canada and Israel and Japan and Australia and New Zealand and other countries through its integrated manufacturing facilities and wide commercial presence .

The company entered the US market through the Caraco acquisition during FY98 and then obtained Taro to access US dermatology markets in FY10 and proceeded with branded specialty milestones such as DUSA in FY13 and Odomzo in FY18 and Ilumya in FY19 and Cequa and Absorica LD in FY20 and Winlevi in FY22 and Sezaby in FY23. Sun Pharma finished acquiring Taro in FY24 to establish it as a complete subsidiary of the company.

Sun Pharmaceutical Industries Limited’s Business Segments

The revenue distribution among business segments in FY25 shows India at 33% and the US at 31% while Emerging Markets account for 18% and Rest of the World brings 14% with API and Others making up 4%. In FY25 India generates 33% of revenues while International operations generate 67%. The RoW market includes Western Europe together with Canada and Israel and Japan and Australia and New Zealand along with other countries .

Sun Pharmaceutical Industries Limited Key Management

• The Chairman and Managing Director position at the company is held by Dilip S. Shanghvi. 

• Aalok D. Shanghvi – Whole-time Director.

• Vidhi Shanghvi serves as Whole-time Director since May 22, 2025.

• C. S. Muralidharan – Chief Financial Officer.

• Anoop Deshpande serves as Company Secretary and Compliance Officer.

Latest Updates on Sun Pharmaceutical Industries Limited

• Through its acquisition of Checkpoint Therapeutics Inc. Sun Pharma acquired UNLOXCYT which represents the first anti-PD-L1 therapy for treating advanced cutaneous squamous cell carcinoma and entered the specialty segment.Sun Pharma finished acquiring Taro during FY24 which resulted in Taro becoming a full subsidiary of Sun Pharma.

• EMA validation of the Marketing Authorisation Application for Nidlegy, finalised on June 3, 2025; Sun is the commercial partner for Europe, New Zealand and Australia for skin cancers.

• The Consumer Healthcare division introduced Revital Cal 500 to the market and launched Pepfix in the sodium alginate antacid category while developing advertising initiatives for Volini and Revital to create market distinctions. Sun Pharma operates in 25+ countries while leading the Indian market as well as maintaining top positions in Romania and Nigeria and Myanmar and India.

• Scientific engagement: presentation of dermatology portfolio abstracts at the 33rd European Academy of Dermatology and Venereology Congress in Amsterdam from September 25, 2024 to September 28, 2024.

• Specialty momentum: US growth driven by Ilumya, Cequa, Winlevi and Odomzo; globally, the contribution of Specialty increased to 20% in FY25 from 18% in FY24 .